Wasatch Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Wasatch Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,208	Closed	-$378K	–	238
2019 Q1	$378K	Sell	11,208 -84,129	-88%	-$2.81M	﹤0.01%	223
2018 Q4	$2.78M	Sell	95,337 -978	-1%	-$43.4K	0.04%	198
2018 Q3	$5.93M	Buy	96,315 +3,933	+4%	+$266K	0.07%	156
2018 Q2	$6.82M	Buy	92,382 +84,017	+1,004%	+$6.55M	0.08%	141
2018 Q1	$549K	Buy	+8,365	New	+$632K	0.01%	269
2017 Q2	–	Sell	-3,053	Closed	-$377K	–	360
2017 Q1	$377K	Hold	3,053	–	–	0.01%	332
2016 Q4	$416K	Hold	3,053	–	–	0.01%	341
2016 Q3	$607K	Sell	3,053 -389	-11%	-$67K	0.01%	326
2016 Q2	$446K	Sell	3,442 -115	-3%	-$12.8K	0.01%	349
2016 Q1	$312K	Buy	3,557 +1,018	+40%	+$111K	﹤0.01%	356
2015 Q4	$515K	Buy	2,539 +9	+0.4%	+$1.61K	0.01%	353
2015 Q3	$368K	Hold	2,530	–	–	﹤0.01%	353
2015 Q2	$538K	Buy	+2,530	New	+$620K	0.01%	359

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wasatch Advisors's BLCM Position: Q2 2019 in Review

Wasatch Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 11,208 shares — an estimated $378K sold.

Wasatch Advisors first reported a position in BLCM in Q2 2015 and held it in 13 quarters. The position peaked at $6.82M in Q2 2018. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Wasatch Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Wasatch Advisors sold 11,208 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $378K.
Wasatch Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 13 quarters.
Wasatch Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $6.82M in Q2 2018.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Wasatch Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.